Media headlines about Oncolytics Biotech (NASDAQ:ONCY) have trended somewhat positive on Sunday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oncolytics Biotech earned a news impact score of 0.01 on Accern’s scale. Accern also gave media coverage about the company an impact score of 48.7015535285678 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several equities research analysts have recently weighed in on ONCY shares. ValuEngine lowered Oncolytics Biotech from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Zacks Investment Research lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Thursday, June 7th.
Shares of ONCY stock traded up $0.54 during trading hours on Friday, hitting $4.84. The company had a trading volume of 131,457 shares, compared to its average volume of 47,854. Oncolytics Biotech has a 12 month low of $3.58 and a 12 month high of $8.55. The firm has a market cap of $71.04 million, a P/E ratio of -5.69 and a beta of 1.81.
About Oncolytics Biotech
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Featured Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.